Horizon Pharma’s MEDI4945 has potential for subcutaneous dosing and reduced immunogenicity?
Horizon Pharma has licensed the global rights to MEDI4945, a pre-clinical, genetically engineered uricase derivative combined with site-specific PEGylation, from…